These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Ondansetron in the treatment of intractable nausea associated with theophylline toxicity. Sage TA; Jones WN; Clark RF Ann Pharmacother; 1993 May; 27(5):584-5. PubMed ID: 8347909 [TBL] [Abstract][Full Text] [Related]
4. Ondansetron in the treatment of theophylline overdose. Brown SG; Prentice DA Med J Aust; 1992 Apr; 156(7):512. PubMed ID: 1532627 [No Abstract] [Full Text] [Related]
5. Antiemetic effect of ondansetron and dexamethasone in gynecologic malignant patients receiving chemotherapy. Pradermdee P; Manusirivithaya S; Tangjitgamol S; Thavaramara T; Sukwattana P J Med Assoc Thai; 2006 Oct; 89 Suppl 4():S29-36. PubMed ID: 17725140 [TBL] [Abstract][Full Text] [Related]
6. An overview of ondansetron for chemotherapy-induced nausea and emesis. San Angel F J Intraven Nurs; 1993; 16(2):84-9. PubMed ID: 8478782 [TBL] [Abstract][Full Text] [Related]
7. Ondansetron for treating nausea and vomiting in the poisoned patient. Reed MD; Marx CM Ann Pharmacother; 1994 Mar; 28(3):331-3. PubMed ID: 8193420 [TBL] [Abstract][Full Text] [Related]
8. Action of ondansetron and CP-99,994 to modify behavior and antagonize cisplatin-induced emesis in the ferret. Lau AH; Kan KK; Lai HW; Ngan MP; Rudd JA; Wai MK; Yew DT Eur J Pharmacol; 2005 Jan; 506(3):241-7. PubMed ID: 15627434 [TBL] [Abstract][Full Text] [Related]
9. Ondansetron in the treatment of nausea and vomiting. Introduction. Marschner N Anticancer Drugs; 1993 Dec; 4 Suppl 2():3-7. PubMed ID: 8136513 [No Abstract] [Full Text] [Related]
10. Oral ondansetron for the control of cisplatin-induced delayed emesis: a large, multicenter, double-blind, randomized comparative trial of ondansetron versus placebo. Navari RM; Madajewicz S; Anderson N; Tchekmedyian NS; Whaley W; Garewal H; Beck TM; Chang AY; Greenberg B; Caldwell KC J Clin Oncol; 1995 Sep; 13(9):2408-16. PubMed ID: 7666101 [TBL] [Abstract][Full Text] [Related]
11. Repetitive oral activated charcoal and control of emesis in severe theophylline toxicity. Amitai Y; Yeung AC; Moye J; Lovejoy FH Ann Intern Med; 1986 Sep; 105(3):386-7. PubMed ID: 3740677 [No Abstract] [Full Text] [Related]
12. Comment: Ondansetron for treating nausea and vomiting in the poisoned patient. Forster ER; Palmer JL Ann Pharmacother; 1994 Oct; 28(10):1203-4. PubMed ID: 7841589 [No Abstract] [Full Text] [Related]
13. A randomized trial of olanzapine versus palonosetron versus infused ondansetron for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation. Nakagaki M; Barras M; Curley C; Butler JP; Kennedy GA Support Care Cancer; 2017 Feb; 25(2):607-613. PubMed ID: 27738796 [TBL] [Abstract][Full Text] [Related]
14. Ondansetron. An update of its therapeutic use in chemotherapy-induced and postoperative nausea and vomiting. Markham A; Sorkin EM Drugs; 1993 Jun; 45(6):931-952. PubMed ID: 7691500 [TBL] [Abstract][Full Text] [Related]
15. Efficacy & tolerability of ondansetron compared to metoclopramide in dose dependent cisplatin-induced delayed emesis. Bhatia A; Tripathi KD; Sharma M Indian J Med Res; 2004 Sep; 120(3):183-93. PubMed ID: 15489556 [TBL] [Abstract][Full Text] [Related]
16. Effectiveness and economy of low-dose ondansetron. Walton SC; Koenig TJ Am J Health Syst Pharm; 1995 Mar; 52(5):546-7. PubMed ID: 7606564 [No Abstract] [Full Text] [Related]
17. Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy. Italian Group for Antiemetic Research N Engl J Med; 2000 May; 342(21):1554-9. PubMed ID: 10824073 [TBL] [Abstract][Full Text] [Related]
18. Ondansetron: a pharmacoeconomic and quality-of-life evaluation of its antiemetic activity in patients receiving cancer chemotherapy. Plosker GL; Milne RJ Pharmacoeconomics; 1992 Oct; 2(4):285-304. PubMed ID: 10147044 [TBL] [Abstract][Full Text] [Related]
19. Pharmacological characterization of RS 25259-197, a novel and selective 5-HT3 receptor antagonist, in vivo. Eglen RM; Lee CH; Smith WL; Johnson LG; Clark R; Whiting RL; Hegde SS Br J Pharmacol; 1995 Feb; 114(4):860-6. PubMed ID: 7773547 [TBL] [Abstract][Full Text] [Related]
20. [Ondansetron (GR 38032F), a competitive 5-HT3 receptor antagonist as an antiemetic in cytostatic drug-induced nausea and vomiting. An open, substance-oriented phase II/III study]. Serve H; Perker M; Ertl A; Reichold M; Fink U; Berdel WE Onkologie; 1990 Oct; 13(5):369-74. PubMed ID: 2150552 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]